How would you measure the success of Color's genetic testing for hereditary cancer risk?

Introduction

Measuring the success of Color's genetic testing for hereditary cancer risk requires a comprehensive approach that considers multiple stakeholders and metrics. To address this product success metrics challenge effectively, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Color's genetic testing for hereditary cancer risk is a direct-to-consumer genetic testing service that analyzes an individual's DNA to identify genetic mutations associated with increased cancer risk. The product involves:

1. Sample collection: Users receive a saliva collection kit at home.
2. Lab analysis: The sample is processed in Color's CLIA-certified lab.
3. Results delivery: Users receive a detailed report on their genetic risk factors.
4. Follow-up support: Genetic counseling and physician consultations are available.

Key stakeholders include:

• Users: Individuals seeking to understand their genetic cancer risk
• Healthcare providers: Doctors who may recommend or interpret test results
• Insurance companies: Potential payers for the test
• Regulatory bodies: Ensuring compliance with health and privacy regulations

User flow:

1. Order kit online
2. Receive and provide saliva sample
3. Return sample for analysis
4. Receive results and interpretations
5. Optional genetic counseling or physician consultation

This product aligns with Color's mission to make genetic information accessible and actionable for improved health outcomes. It competes with other genetic testing companies like 23andMe and Invitae, but focuses specifically on health-related genetic markers.

The product is in the growth stage of its lifecycle, with increasing adoption but still room for market expansion and feature enhancement.